◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › MDXG

MiMedx Group, Inc. (MDXG) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-20

MiMedx Group, Inc. (MDXG) operates in the Biotechnology industry and is headquartered in Marietta, United States with about 808 employees. Its market capitalization is roughly $640 million. In the fiscal year ended 2025-12-31, MDXG reported $419M in revenue and $49M in net income.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.

Interactive charts & full statements → Open the MDXG valuation workbench →

MDXG Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$419M$349M$322M$268M
Gross Profit$346M$289M$267M$220M
Operating Income (EBIT)$64M$59M$37M($15M)
Net Income$49M$42M$58M($30M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MDXG Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$59M$118M$114M$99M$88M
Gross Profit$42M$99M$95M$80M$72M
Operating Income (EBIT)($16M)$21M$22M$12M$8M
Net Income($11M)$15M$17M$10M$7M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MDXG Free Cash Flow History

MDXG Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$343M$264M$239M$171M
Total Liabilities$86M$71M$96M$189M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MDXG viewer.

Other Companies in Biotechnology

← MDWDAll stocksMDXH →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.